Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Patheon Announces Completion Of MOVA Pharmaceutical Acquisition

By Pharmaceutical Processing | January 20, 2005

Patheon Inc. recently completed the acquisition of MOVA Pharmaceutical Corporation, a leading U.S. prescription pharmaceutical contract manufacturer located in Puerto Rico, U.S.A.

“This acquisition marks a major achievement in Patheon’s growth strategy,” said Robert Tedford, Chief Executive Officer, Patheon Inc. “It transforms Patheon, creating one of the world’s largest independent providers of integrated pharmaceutical development and manufacturing services.

“MOVA Pharmaceutical brings to Patheon considerable industry knowledge and manufacturing expertise, three additional FDA-approved facilities in the U.S.A. and excellent long-term client relationships,” Mr. Tedford said. “With the addition of MOVA, we now have 14 manufacturing facilities and 5,600 highly skilled employees to serve the world’s largest pharmaceutical sales markets – the U.S.A. and Europe. We have enhanced our capability to meet the growing demand of global pharmaceutical and biotechnology companies for drug manufacturing and development services.

“Reflecting our commitment to enhancing shareholder value, this agreement is a major strategic initiative that will expand our client base and is expected to be significantly accretive to earnings per share in fiscal 2005,” Mr. Tedford said.

The purchase price for the acquisition was based on an enterprise value for MOVA at closing of $350 million. Patheon issued 12,684,866 common shares to MOVA’s shareholders in satisfaction of $81.5 million of the purchase price. Patheon assumed approximately $131.3 million in debt and related costs. Patheon also paid $137.2 million in cash at closing.The purchase price may be increased to a maximum of US$441 million, based on earn-out arrangements relating to MOVA’s results of operations for fiscal 2004 and the first six months of fiscal 2005. Patheon paid into escrow $74.7 million to support the potential payments under the earn-out arrangements. Patheon funded the acquisition through a combination of debt and equity financing.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE